Parexel expands real-world research capabilities with new leadership

New Delhi: Parexel is strengthening its Real World Research (RWR) offering by integrating its Scientific Data Organization (SDO) and Real World Evidence (RWE) capabilities.

This strategic alignment addresses the growing demand for evidence-based solutions that enhance drug development processes across the product lifecycle, ensuring safety and efficacy.

Through this integration, Parexel aims to optimize its research methodology across primary site-based real-world research and secondary data/non-site-based research. 

Leading this expanded focus on Real World Research is Mike D’Ambrosio, who has been appointed as Senior Vice President and Global Head, Real World Research. In his new role, D’Ambrosio will be responsible for enhancing customer engagement and overseeing the delivery of Real World Data (RWD) and Real World Evidence services. His focus will be on improving the understanding of patient experiences and outcomes, which are crucial for ensuring that new medicines are both safe and effective.

D’Ambrosio highlighted the importance of RWE strategies in managing the complexities of drug development and meeting the varying needs of stakeholders throughout the product lifecycle. He explained that generating high-quality RWE across primary, secondary and hybrid data collection methodologies can accelerate development timelines, reduce risks, and differentiate medicines in real-world settings. 

“Parexel’s long history and significant expertise in scientific, methodological, analytical, and operational areas uniquely position the company as a trusted partner for evidence-generation strategies, delivery and dissemination,” D’Ambrosio noted. He expressed his enthusiasm for leading a talented team to strengthen Parexel’s position as a leader in real-world evidence generation.

Before joining Parexel, D’Ambrosio served as Vice President, Head of Real World Evidence Solutions at Syneos Health, where he spent over eight years in various roles in operations, consulting, and leadership. Most recently, he led Syneos Health’s RWE solutions consultancy group, where he oversaw strategy and delivery across real-world evidence, health economics and outcomes research, epidemiology, and data sciences. His work included spearheading thought leadership in RWE and promoting its adoption throughout the product development process. D’Ambrosio also played a key role in securing preferred provider partnerships as part of Syneos Health’s Real World Data strategy in Europe.

Stephen Pyke, Parexel’s Chief Clinical Data and Digital Officer, underscored the importance of real-world data in understanding patient experiences, particularly in the development of high-cost, complex therapies. Pyke noted that as the demand for RWE continues to grow, Parexel’s Real World Research team will focus on forming strategic collaborations across the industry and adapting to the evolving needs of the healthcare landscape. “Mike’s extensive experience in this field makes him a valuable addition to our team,” Pyke added. “We are committed to driving innovation and providing valuable insights through RWE for our customers worldwide.”